If most of selling is from Canada dilution they got their shares at $0.60. Market cap doesn’t suggest for price to go much lower IMO. I don’t see this getting over $2.50 even in February and possibly $5 a little over a year if we can gain revenue traction in Cali with 4 labs and Mass.
Compared to KS*B market cap of $460M and revenues of $51M. With $10M revenues for EVIO and same multiplier of 9x that gives a $90M market cap and a share price of about $4.50 in about a year from now without more dilution. With $15 million in revenue with current share structure and labs that’d be $6.75 a share.
The question is how much revenue can 4 Cali labs, 1 of 5 mass labs, 4 of 21 Oregon labs, and 60% of a lab by Aurora can bring in once all up and running (waiting on 2 Cali labs and Mass). If that brings in $5m in revenue we are at $2.25 a share. I see that as minimal in a year and wishful thinking of $7 in a little over a year.
So the question right now is how far along are the Cali labs that could be bringing in revenue NOW and were targeted to be open by October 1st?!
Market Data 
Markets 
AI
